Suchergebnisse - "Menzies-Gow, Andrew"

PubPharm (12)

1

Reply to "Exploring the long-term effects of biologic initiation in severe asthma : Insights from the International Severe Asthma Registry"

enthalten in: The journal of allergy and clinical immunology. In practice | 2024

von Chen, W. | Tran, T. | Sadatsafavi, M. | +62

2

Not just an anti-eosinophil drug : tezepelumab treatment for type 2 asthma and beyond

enthalten in: The European respiratory journal | 2023

von Corren, J. | Brightling, C. | Boulet, L. | +8

3

A Response to : Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab"

enthalten in: Advances in therapy | 2022

von Menzies-Gow, A. | Hoyte, F. | Price, D. | +7

CommentOn: Adv Ther. 2022 May;39(5):2065-2084. - PMID 35287231

4

The carbon footprint of respiratory treatments in Europe and Canada : an observational study from the CARBON programme

enthalten in: The European respiratory journal | 2022

von Janson, C. | Maslova, E. | Wilkinson, A. | +7

5

Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy - Authors' reply

enthalten in: The Lancet. Respiratory medicine | 2022

von Menzies-Gow, A. | Kreindler, J. | Katial, R. | +1

CommentOn: Lancet Respir Med. 2022 Jan;10(1):47-58. - PMID 34619104

6

Biologics in severe asthma : Which one, When and Where?

enthalten in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology | 2021

von Rupani, H. | Murphy, A. | Bluer, K. | +8

7

Asthma-related sudden death in athletes : a retrospective analysis of the US NCCSIR database (1982-2018)

enthalten in: The European respiratory journal | 2021

von Price, O. | Kucera, K. | Price, H. | +3

8

The Severe Asthma Questionnaire : sensitivity to change and minimal clinically important difference

enthalten in: The European respiratory journal | 2021

von Masoli, M. | Lanario, J. | Hyland, M. | +8

9

Unmet need in severe, uncontrolled asthma : can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?

enthalten in: Respiratory research | 2020

von Menzies-Gow, A. | Wechsler, M. | Brightling, C.

10

Objective testing is cost effective

enthalten in: BMJ (Clinical research ed.) | 2018

von Menzies-Gow, A. | Alexander, J.

CommentOn: BMJ. 2018 Jan 9;360:k29. - PMID 29317387